Literature DB >> 20079791

QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia.

Yuji Ozeki1, Kumiko Fujii, Naoki Kurimoto, Naoto Yamada, Masako Okawa, Takesuke Aoki, Jun Takahashi, Nobuya Ishida, Minoru Horie, Hiroshi Kunugi.   

Abstract

Many antipsychotic drugs cause QT prolongation, although the effect differs based on the particular drug. We sought to determine the potential for antipsychotic drugs to prolong the QTc interval (>470 ms in men and >480 ms in women) using the Bazett formula in a "real-world" setting by analyzing the electrocardiograms of 1017 patients suffering from schizophrenia. Using logistic regression analysis to calculate the adjusted relative risk (RR), we found that chlorpromazine (RR for 100 mg=1.37, 95% confidence interval (CI)=1.14 to 1.64; p<.005), intravenous haloperidol (RR for 2 mg=1.29, 95% CI=1.18 to 1.43; p<.001), and sultopride (RR for 200 mg=1.45, 95% CI=1.28 to 1.63; p<.001) were associated with an increased risk of QTc prolongation. Levomepromazine also significantly lengthened the QTc interval. The second-generation antipsychotic drugs (i.e., olanzapine, quetiapine, risperidone, and zotepine), mood stabilizers, benzodiazepines, and antiparkinsonian drugs did not prolong the QTc interval. Our results suggest that second-generation antipsychotic drugs are generally less likely than first-generation antipsychotic drugs to produce QTc interval prolongation, which may be of use in clinical decision making concerning the choice of antipsychotic medication. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20079791     DOI: 10.1016/j.pnpbp.2010.01.008

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  33 in total

1.  Molecular analysis of potassium ion channel genes in sudden death cases among patients administered psychotropic drug therapy: are polymorphisms in LQT genes a potential risk factor?

Authors:  Sayako Kamei; Noriko Sato; Yuta Harayama; Miyako Nunotani; Kanae Takatsu; Tetsuya Shiozaki; Tokutaro Hayashi; Hideki Asamura
Journal:  J Hum Genet       Date:  2013-11-28       Impact factor: 3.172

Review 2.  Clinically significant drug interactions with atypical antipsychotics.

Authors:  William Klugh Kennedy; Michael W Jann; Eric C Kutscher
Journal:  CNS Drugs       Date:  2013-12       Impact factor: 5.749

3.  A computerized physician order entry set designed to improve safety of intravenous haloperidol utilization: a retrospective study in agitated hospitalized patients.

Authors:  Andrew J Muzyk; Sarah K Rivelli; Wei Jiang; Heather Heinz; Amber Rayfield; Jane P Gagliardi
Journal:  Drug Saf       Date:  2012-09-01       Impact factor: 5.606

4.  QTc prolongation in short-term treatment of schizophrenia patients: effects of different antipsychotics and genetic factors.

Authors:  Ilja Spellmann; Matthias A Reinhard; Diana Veverka; Peter Zill; Michael Obermeier; Sandra Dehning; Rebecca Schennach; Norbert Müller; Hans-Jürgen Möller; Michael Riedel; Richard Musil
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-02-10       Impact factor: 5.270

Review 5.  Mechanisms Underlying the Actions of Antidepressant and Antipsychotic Drugs That Cause Sudden Cardiac Arrest.

Authors:  Serge Sicouri; Charles Antzelevitch
Journal:  Arrhythm Electrophysiol Rev       Date:  2018-08

Review 6.  QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes.

Authors:  Katharina Wenzel-Seifert; Markus Wittmann; Ekkehard Haen
Journal:  Dtsch Arztebl Int       Date:  2011-10-14       Impact factor: 5.594

7.  Frequency of use of QT-interval prolonging drugs in psychiatry in Belgium.

Authors:  Eline Vandael; Thomas Marynissen; Johan Reyntens; Isabel Spriet; Joris Vandenberghe; Rik Willems; Veerle Foulon
Journal:  Int J Clin Pharm       Date:  2014-05-08

8.  Effect of selection of QTc formula on eligibility of cancer patients for phase I clinical trials.

Authors:  Mitesh J Borad; Arundhati D Soman; Martin Benjamin; Daniel Casa; Waibhav D Tembe; Barbara F Piper; Ramesh Ramanathan; Raoul Tibes; Gayle Jameson; Karen Ansaldo; Daniel D Von Hoff
Journal:  Invest New Drugs       Date:  2012-12-16       Impact factor: 3.850

9.  Emerging role of sertindole in the management of schizophrenia.

Authors:  Stephanie L Cincotta; Joshua S Rodefer
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

10.  Risk management of QTc-prolongation in patients receiving haloperidol: an epidemiological study in a University hospital in Belgium.

Authors:  Eline Vandael; Bert Vandenberk; Joris Vandenberghe; Isabel Spriet; Rik Willems; Veerle Foulon
Journal:  Int J Clin Pharm       Date:  2016-01-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.